All COVID-19 articles
-
NewsUS COVID-19 school closures were not cost-effective - but other non-pharmaceutical interventions were
School closures during the COVID-19 pandemic imposed enormous long-term costs while other measures delivered better health outcomes for far less money, according to new research analysing non-pharmaceutical interventions in the United States.
-
NewsResearchers uncover how COVID-19 may linger in cancer patients and affect treatment outcomes
New research is providing important insights into how COVID-19 persists in cancer patients even long after testing positive. Researchers studied three cancer patients who had undergone transplant therapies and were hospitalized with severe COVID-19 infections.
-
NewsResearchers map key human proteins that power coronavirus replication, pointing to new treatment strategies
Scientists have pinpointed dozens of human proteins that SARS-CoV-2 needs to complete its full life cycle, from entering a cell to replicating and releasing new viral particles.
-
NewsProtein discovery gives new hope for longer COVID protection
Scientists have discovered that the body’s immune system strongly reacts to an internal protein from SARS-CoV-2, the virus that causes COVID-19, which mutates less frequently than the surface-spike protein currently targeted by vaccines.
-
NewsClinical study shows that nasal spray containing azelastine reduces risk of coronavirus infection by two-thirds
In addition to showing a marked reduction in coronavirus infections, the azelastine group also displayed fewer symptomatic SARS-CoV-2 infections, a lower overall number of confirmed respiratory infections, and, unexpectedly, a reduced incidence of rhinovirus infections, another major cause of respiratory illness.
-
NewsNew research makes first broad-spectrum antiviral
A new study offers a promising path toward the development of the world’s first broad-spectrum antiviral (BSA), which could be deployed against a wide range of deadly viruses, including future pandemic threats.
-
NewsCommon cold may protect against COVID-19 according to researchers
A new study has found that recent infection with the common cold — often caused by rhinoviruses — may offer temporary protection against infection with SARS-CoV-2, the virus that causes COVID-19.
-
NewsMount Sinai creates first manual for treating infection-associated chronic illness for clinicians
Mount Sinai has launched the country’s first clinical manual for treating infection-associated chronic illnesses (IACIs). This comprehensive guide, prepared by the Cohen Center for Recovery From Complex Chronic Illnesses, part of the Department of Rehabilitation and Human Performance, will help clinicians better diagnose and care for patients with conditions such ...
-
NewsBroad COVID-19 vaccination makes economic sense, especially for older adults, study finds
Vaccinating every person over 65 would actually save the U.S. money, while vaccinating all younger adults would be a reasonable investment, according to a new study.
-
NewsStudy: Long COVID remains a substantial financial and medical burden
Individuals with long COVID-19 experienced worse financial and employment outcomes – lasting up to three years after their initial infection. Notably, vaccination against COVID-19 was associated with strikingly improved work and financial outcomes.
-
NewsWhat exactly is Long COVID? It depends who you ask
New research finds that the definition of Long COVID varies so widely across published studies that the percentage of people identified as having the condition can differ dramatically, making it harder to treat patients and advance research.
-
NewsResearchers identify a potential biomarker for long COVID
Researchers have identified a potential biomarker for long COVID. The study results detail the detection of SARS-CoV-2 protein fragments within extracellular vesicles (EVs) — tiny, naturally occurring packages that help cells share proteins, metabolites, and other materials.
-
NewsGlobal Virus Network reaffirms support for mRNA vaccines and collaborative vaccine research
The Global Virus Network (GVN) has announced that it is unequivocally committed to the continued development and deployment of mRNA vaccines and the global scientific collaboration that makes such innovation possible.
-
NewsLab-made sugar-coated particle blocks Covid-19 infection — Possible new treatment on the horizon
Groundbreaking research has revealed a synthetic glycosystem — a sugar-coated polymer nanoparticle — that can block Covid-19 from infecting human cells, reducing infection rates by nearly 99%.
-
NewsScientists develop new approach to fighting many viruses at once
Scientists have developed a research pipeline to fuel the development of “universal vaccines,” that would address broad viral families and mutated viral variants.
-
NewsRNA immunity: A silent defender against viruses in mammals
Researchers propose that small RNA molecules play a direct and specific role in fighting viral infections in mammals. RNA immunity relies on the base-pairing precision of small RNA fragments, such as microRNAs, to recognize and suppress viral genetic material.
-
NewsQ&A: Why do symptoms linger in some people after an infection?
A new review highlights that long COVID and ME/CFS share many of the same biological problems such as inflammation in the brain, issues with how cells produce energy, and problems with the immune system.
-
NewsClinical trial finds safe, effective treatment for children with severe post-Covid syndrome
Researchers have discovered that a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID. A small, randomized clinical trialfound the oral drug larazotide was both safe and effective in treating children with MIS-C.
-
NewsMucosal vaccine shows transient action against Covid-19 variant
Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings, a new study reveals.
-
NewsStudies confirm influence of country of origin on trust in COVID-19 vaccines
During the pandemic, a preference for domestic vaccines or those from countries such as the United States, Germany, and the United Kingdom was observed for the first time. This phenomenon is known in marketing as the country of origin effect.